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Summary Recombinant interleukin 2 (rIL-2) and flavone acetic acid (FAA) were used to treat 34 patients
with progressing metastatic melanoma. Five patients had solely non-visceral disease and the median number of
organ sites involved was two. Five doses of rIL-2 were given, the first dose intrasplenically via a femoral artery
catheter with a further dose 4 h later i.v. and the other doses i.v. on alternate days. The rIL-2 dose was
11 x 106 Cetus units m-2; the day before rIL-2, FAA (4.8 G m-2) was given as a 6 h i.v. infusion, in order to
enhance further killer cell activity. A total of three courses at 21-day intervals was planned and 74 courses in
all were given. Despite the high dose of rIL-2 and the potential overlapping toxicity affecting blood pressure
with the addition of FAA, side-effects were generally mild. There were only five episodes of grade 4 toxicity:
one of ventricular tachycardia and four other episodes of transient biochemical or haematological disturbance.
Grade 3 hypotension or hypertension occurred on 22 courses but again was transient. No patient required
intensive care facilities. Five patients had tumour response, one being complete. Responses occurred in
pulmonary and hepatic metastases, but mainly in non-visceral sites. Eleven patients remain alive at 6-17
months and in five there is no relapse or progression of disease. Despite the impressive results in animal
tumour models, the addition of FAA to rIL-2 in the present study has not markedly improved results over
rIL-2 alone.
Interleukin-2 (IL-2) is the principal component of the T cell
growth factor (Morgan et al., 1976). Lymphokine activated
killer (LAK) cells can be are generated by the incubation of
human peripheral blood lymphocytes with IL-2. These cells
are capable of lysing fresh, natural killer (NK) cell resistant,
tumour cells but not normal cells (Grimm et al., 1982). High
dose rIL-2 either alone or in combination with LAK cells has
now been used to treat a number of patients with advanced
cancer resistant to conventional therapies, resulting in im-
pressive tumour responses (Rosenberg et al., 1987). A recent
update indicates that some of these patients are alive 3 years
or more following treatment (Rosenberg et al., 1989). How-
ever, the treatment was associated with serious side-effects
which on occasions required intensive care facilities. Never-
theless, there were five partial remissions in 16 patients with
advanced melanoma. There are considerable logistic
difficulties in generating the LAK cells which require
repeated leucophereses followed by rIL-2 in vitro incubation
and re-infusion of the cultured cells. In our previous phase
I/II study using rIL-2 intrasplenically and intravenously,
there were four partial responses (although in only one did
all disease sites respond) and eight patients with stable
disease out of a total of 31 patients with previously progress-
ing advanced melanoma. Five patients remain alive at 10-16
months (Thatcher et al., 1989a). The intrasplenic route was
used to try and generate LAK cells in vivo rather than
employing the cumbersome in vitro technique, high dose
rIL-2 was then administered intravenously on alternate days
without major toxicity.
New approaches for the treatment of advanced melanoma
are urgently needed, given the rapid increase in incident of
this tumour and the poor impact of chemotherapy even at
high dose (Thatcher et al., 1989b). The observation that
flavone acetic acid (FAA) enhances organ associated NK cell
activity, including activity within the spleen, was therefore of
interest (Ching & Baguley, 1987; Hornung et al., 1988; Wilt-
rout et al., 1988). FAA and rIL-2 together were found to be
curative in mouse renal cancer whereas either agent alone
was ineffective (Wiltrout et al., 1988). FAA, a synthetic
flavonoid, is known also to have unexpectedly high activity
against a variety of murine tumours including melanoma
(Plowman et al., 1986; O'Dwyer et al., 1987). The anti
tumour mechanism of FAA is still unknown although the
action is likely to be indirect and the material can best be
considered a biological response modifier (Finlay et al., 1988;
Hornung et al., 1988). Indeed, FAA will induce haemorr-
hagic necrosis of mouse tumour metastases in vivo (Smith et
al., 1987), a feature similarly found with tumour necosis
factor. Phase I and clinical pharmacology studies of intra-
venous FAA are available (Kerr et al., 1987; Weiss et al.,
1988) and NK activity in human blood has been enhanced by
FAA (Urba et al., 1988). Other features of FAA which are of
advantage clinically include the lack of alopecia and
myelosuppression although hypotension and lethargy are the
dose limiting toxicities (Kerr et al., 1987; Weiss et al., 1988).
Given the alternate day administration schedule of our
previous rIL-2 study, and the experimental, immunogical and
clinical data for FAA, it was considered reasonable to com-
bine both agents. The NK activity was known to peak at
about 24 h after FAA in the murine renal cell model (Wilt-
rout et al., 1988) and there were significant increases in NK
activity by 24 h in three of six patients examined by Urba et
al. (1988). The maximum tolerated dose in our previous
alternate day rIL-2 study was 10.9 x 106 Cetus units m2.
Maximum tolerated doses determined for FAA depended on
the administration schedule, i.e. 6.4 G m2 given i.v. over I h
or 3 h every week for a minimum of 3 weeks or up to
10 G m-2 when infused over 6 h (Kerr et al., 1987; Weiss et
al., 1988). Following further discussion (S. Kaye, personal
communication) it was considered that the FAA dose should
be 4.8 G m-2 as a 6 h infusion on the days before the IL-2
doses. We now report on the results of a phase II study using
FAA and IL-2 in advanced malignant melanoma.
Materials and methods
Patientpopulation
Thirty-four patients with metastatic, progressing melanoma
were entered into this study which commenced in January
1988 and was completed in March 1989. All patients had
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clinically evaluable disease and none had received anti-
tumour treatment within 4 weeks before study entry. Nine
patients had received previous DTIC melphalan with or with-
out local radiotherapy. There were 19 male and 15 female
patients with a median age of 45 years (range 26-67 years).
To be eligible all patients had to have a Karnofsky score
>,50, be without major cardio respiratory disease of non-
oncological nature and have no obvious CNS metastases,
although routine CT brain scans were not performed. Pre-
treatment investigations included routine haematology and
biochemistry with isotope and other scans as necessary to
measure and evaluate disease. The metastatic pattern in the
34 patients is shown in Table I; only five patients had solely
non-visceral disease ie metastases limited to skin, superficial
soft tissues and peripheral lymph nodes.
Interleukin-2
The rIL-2 was kindly supplied by Eurocetus Corporation,
Amsterdam, and the administration over 1 h has been de-
scribed previously (Thatcher et al., 1989a). Briefly, the first
rIL-2 dose was given via a catheter (femoral approach) posi-
tioned in the splenic artery, four hours later a further dose
was given intravenously by three alternate day i.v. doses. A
complete treatment course therefore involved five rIL-2
administrations over a 6 day period. The day before each
rIL-2 administration, FAA (kindly supplied by Lipha, Lyon)
at a dose of 4.8 G m-2 with light protection was given as a
6 h i.v. infusion. Four FAA infusions per course were given.
Alkalinisation of urine was used to prevent possible renal
damage by FAA by giving 500 ml 1.26% sodium bicarbonate
i.v. over 1 h before and after the FAA infusion the latter
being given in 500 ml normal saline. Treatment was repeated
for a maximum of three courses at 21-day intervals from the
start of the FAA.
Supportive care
Pyrexia was controlled with paracetamol and no anti
inflammatory agents were used. Moderate to severe blood
pressure changes (grade 3) were treated conservatively by
stopping any infusion and when required by the addition of
normal saline over 30-40 min. No specialised monitoring
was undertaken and patients were treated on a general
medical oncology ward. Regular recording of the patient's
general status and vital signs while on treatment were per-
formed as previously (Thatcher et al., 1989a). Following
relapse or progression DTIC 250 mgm-2 i.v. daily for 5 days
with melphalan 15mgm2 i.v on day 3 or other palliative
therapy was considered.
Response toxicity evaluation andfollow-up
Response and toxicity was evaluated by using standard
WHO criteria. Stable disease followed the definition of 'no
change', i.e. no significant change for at least 4 weeks,
estimated decrease of less than 50%, and lesions with
estimated increase of less than 25% (Miller et al., 1981). The
time of onset and duration of any side efects were also
recorded and when possible ascribed to either a rIL-2 or
Table I Patient details
Metastatic
sites
D,P
N4,P,S,
p
N4, P
D,N2,0
N4,O,Si
H,O
D,H,P
D,N,4,S
A,N, 4,S
N14
D,N,
H,Sp
N4
O,P,S,Si
D,H,N234,O,P
D,N4,P
D,S
A,D,N1.4
N4,O,S
D,N2,0,S,Sp
N2,4,S
H,N,,
N4
D,N2
D,H,M,N,,O,P,Sp
D,S
H,S
N,,P
N3
D,N2,S
H,N,
D,H,N1.4,S
M,O
BSA
(m2)
1.9
1.8
1.9
1.7
1.9
1.5
1.5
1.9
1.7
1.5
1.6
2.0
2.0
1.8
1.8
1.7
1.6
1.6
1.9
1.8
1.9
2.0
2.1
1.7
1.8
1.7
1.8
1.9
1.7
1.9
1.8
2.0
1.9
1.9
No. of
courses
given
3
3
3
2
2
2
3
3
3
2
2
2
2
3
3
2
3
3
3
2
3 3
3
3
2
3
Overall
response with
courseno.
PR (2)
p
p
p
p
S (2)
p
p
S2 (1)
S' (2)
p
p
p
S (2)
P
p P
PR (2)
p
SI (l)
P2
S (2)
S (2)
p
PR (2)
p
S3 (2)
p
PR (3)
CR (2)
p
S (2)
Duration of Survival
CR/PR/S Status (months)
7 D 13
D 4
D I
D 3
D 4
2 D 7
D 3
D 3
2 D 4
10+ A 11
D 4
D 2
D 1
2 D 11
D 12
D 2
14 A 16
A 7
2 D 11
3 A 17
D 4
A 12
D 4
9+ A 11
2 A 6
D 2
8 A 10
D 1
5+ A 7
D 4
3+ A 6
4+ A 6
D 4
1 D 3
Sites: A, adrenal; D, skin; H, liver; M, marrow; N, nodes; 1, regional; 2, peripheral (not 1); 3,mediastinal;
4, intra-abdominal; 0, bone; P, pulmonary; S, soft tissue; Si, small intestine; Sp; spleen; BSA, body surface
area. Overall response: P, progression (P', pulmonary metastases responded; P2, nodal metastases
responded; other sites progressed); S, stable (S', nodal and soft tissue sites responded; S2, skin sites
responded; S3, nodal sites responded; other sites remained static); CR, complete reponse; PR, partial
response; ( ) indicates course number that response was noted; + indicates no relapse or progression. A,
alive; D, dead. Patient nos 5, 9, 13-15, 18-20, 22, 23, 25, 26 received chemotherapy on progression with
partial response in patient nos 15, 20, 22.
Pat.
no.
l
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
.33
34
Age
44
42
44
65
36
47
50
44
45
63
62
57
49
45
43
40
58
41
45
64
29
60
47
49
48
26
67
42
57
41
46
40
44
28
Sex
M
F
M
F
M
F
F
M
M
F
F
M
M
F
M
F
F
F
M
F
M
F
M
F
M
M
M
F
F
M
M
M
M
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FAA administration. Hypotension and hypertension was
scored as indicated in the results section. Blood counts and
biochemistry were performed at the start of treatment and
weekly between courses. The performance score was also
assessed before and after treatment (Miller et al., 1981).
Follow-up visits following completion of the protocol were at
4-6 week intervals for the first 6 months and every 2-3
months thereafter.
Results
Response
In the study group of 34 patients there was one patient with
complete response (3%), which occurred in both peripheral
lymph nodes an hepatic metastases (confirmed on CT scan).
In four other patients partial response (12%) occurred. Res-
ponses occurred predominantly in non-visceral metastases,
i.e. nodes, skin and soft tissue, although lung metastases also
responded. The majority of these responses were noted after
the second course. Seven other patients showed response in
one or more sites, particularly soft tissue areas but with
progression or stable disease elsewhere (see Table I). Three
patients (out of 12) who received chemotherapy with DTIC
and melphalan had a partial response (see Table I). The
lymphocyte count was also examined in those patients who
did not progress (44%: five patients who responded and 10
with stable disease) and the 19 patients (56%) in which
progression occurred during treatment. There were no
obvious differences between the median lymphocyte values
between these two patient groups, but there was considerable
change in the lymphocyte count with treatment (Figure 1).
There were no significantly differences between the lym-
phocyte counts on day 0, 21 and 42, i.e. immediately before
a rIL-2 course, and the counts 14 days later (Wilcoxon
matched pairs signed ranks test, two-tailed P >0.260). The
median survival of all 34 patients is 4 months with a range of
1-17 months. Eleven patients remain alive at 6-17 months
and in five of these patients there is no relapse or progression
of disease (see Table I).
Toxicity
A total of 74 courses of rIL-2 and FAA were given and 15
patients received all three courses. Thirty-three individual
doses of rIL-2 out of a possible maximum of 370 (9%) were
not given and 19 (6%) doses of FAA out of a 296 possible
maximum were omitted due to toxicity. In two patients the
FAA dose was reduced by 20% on nine occasions because of
myalgia and marked malaise. There were five episodes of
grade 4 life-threatening toxicity (see Table II). The one
patient who developed transient ventricular tachyardia was
later shown on autopsy to have myocardial metastases;
another patient developed grade 4 thrombocytopenia and
0 a
en
o n a)>
E aE- :_
0
Course 1
Figure 1 Lymphocyte count during rIL-2 treatment.
patients with progressive melanoma. ----, patients with stable or
responding melanoma.
Table 11 Toxicity profile of the 74 courses
Number ofcourses with WHO grades
0 1 2 3 4
Hb 37 18 14 5
WBC 69 3 1 - I
Platelets 67 3 2 1 1
Bilirubin 72 2
Aspartate 54 13 5 2
transaminase
Creatinine 66 6 2 -
Nausea/vomiting 20 16 36 2
Diarrhoea 54 13 7
Neurotoxicity
Peripheral 64 8 1 1
Consciousness 64 3 4 3
Fever 2 8 54 10
Pulmonary 67 2 1 4
Cardiac 72 1 - -
Hypotensiona 29 20 13 12
Hypertensionb 62 2 5 5
aHypotension grades 1, >20 mmHG systolic change or light
headedness; 2, >30 mmHg systolic change or orthostatic symptoms
with pulse increase > 15 with upright posture; 3, >40 mmHg systolic
change or requires fluid therapy. bHypertension grades 1, > 10 mmHg
increase; 2, > 10-25 mmHg increase in systolic or diastolic with no
symptoms; 3, >25 mmHg increase in systolic or diastolic with no or
minor symptoms.
leucopenia but had marrow metastases. There were two
patients with 10-fold increases in the AST level; again these
abnormalities were transient. There were no other major
problems occurring in the haematological or biochemical
parameters (see Table II). In particular renal function was
mildly and transiently impaired on only eight occasions and
there was no weight gain of 5% or more. The other toxicities
are shown in Table II. There were four episodes of severe
dyspnoea occurring at rest soon after rIL-2 administration,
and the severe neurotoxicity which occurred on five occasions
was again mainly a feature of rIL-2 and was transient.
Arthalgia and myalgia was reported on direct questioning on
27 courses. In five patients there was a rapid development of
a dry, itchy, desquamating rash lasting for up to 10 days.
These symptoms were not clearly associated with the marked
eosinophilia (>20% of the total WBC) which occurred on
16 courses. No patient developed positive auto-antibodies
although screening was not performed in every patient. Other
side-effects, i.e. gastrointestinal, fever and so forth, were
either absent or mild on the large majority of courses (see
Table II).
The most worrying toxicity concerned blood pressures
changes, which were of a severe grade on 17 occasions. The
main problem was hypotension with the FAA administration
(see Table II). However, this severe grade of blood pressure
change lasted for less than half an hour although there was
perturbation of some degree for several hours. The duration
of side-effects was generally very short but in the occasional
patient lasted a day or more. In most cases, side-effects
occurred within 2-3 h of starting rIL-2 or FAA, although
the onset of diarrhoea and neurotoxicity was somewhat
longer (4-5 h) and the ventricular tachycardia started 8 h
after the rIL-2 treatment. The duration of side-effects after
either the rIL-2 or FAA was generally quite short and only
fever (of a mild degree) persisted for a median duration of
more than 12 hours. The patients' major complaints were of
myalgia and a general feeling of lethargy which persisted
during the week of treatment. There was no evidence of
worsening toxicity with subsequent courses although there
was the impression that the patients became more lethargic
throughout the week of treatment, particularly on the second
and third courses. There was one episode of transient lower
limb embolism associated with splenic artery catheterisation.
In two patients (numbers 20 and 32) catheterisation was not
technically possible and the rIL-2 dose was given intra-
venously.
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immediately at the end of the week's therapy and again just
before the next course. The treatment itself did not appear to
impair performance status. The Karnofsky scores were com-
pared before treatment and at 1 month after treatment.
Patients who died were included and scored as zero. The
score was unchanged in 12 patients but did decrease in a
further 12, whereas in the remaining 10 the score increased
by at least two levels and four patients returned to complete-
ly normal activity.
Discussion
The current study of rIL-2 and FAA in metastatic melanoma
is the first report of this experimentally attractive combina-
tion. The current study immediately followed our previous
investigation which used rIL-2 alone (Thatcher et al., 1989a).
The addition of FAA did not require lower rIL-2 doses to be
used. Indeed, the median cumulative dose of rIL-2 in the
present study with FAA was 12.0 x 107 U m-2 (range
33-165) with 9% of doses being omitted because of toxicity.
These values are very similar to the preceding phase II, rIL-2
alone study, with a cumulative dose of 14.0 x 107 Um2
(range 1-165) and 11% of doses omitted, although these
data were only from 16 patients. These median cumulative
doses of rIL-2 are comparable to the dose given per patient
in Rosenberg's series (8-9 x 107 U m-2), although the dose
was administered over a median of one course rather than
two in our studies (Rosenberg et al., 1987). In this study it
was not possible to determine the influence of the intrasplenic
dose on the patients' disease activity or on lymphocyte count.
The two patients who did not receive intrasplenic doses are
alive at 6 and 17 months.
There was no marked increase in toxicity following the
addition of FAA and again no intensive care facilities were
required. Despite the potential for aggravation of common
side-effects, i.e. blood pressure, there was no major increase
in grade 3 hypotension (20%) with FAA and rIL-2 versus
17% with rIL-2 alone in our previous study (Thatcher et al.,
1989a). However, hypertension of grade 3 severity was noted
on 8% of courses with the combination, and 9% with rIL-2
alone but of lower grade. Again, severe dyspnoea did not
increase with the addition of FAA but there did appear to be
an increase in myalgia and arthralgia (81% of courses with
the FAA, rIL-2 combination) compared with 61% with rIL-2
alone. This side-effect was the most troublesome for the
majority of patients and was only partly controlled with
paracetamol.
Fifty-six per cent of patients with FAA were progressers
compared with 61% in the previous rIL-2 alone study. There
were, however, more responders (15%), including one com-
plete response (Thatcher et al., 1989a). Another feature of
both studies was the number of patients whose disease was
progressing before treatment, but stabilised at least in some
patients for many months. No statistically significant
differences in the lymphocyte count or other immunological
parameters between progressers and non-progressers were
noted in this study or previously (Ghosh et al., 1989). Other
investigators (West et al., 1987) have suggested that marked
'overshoot' in the lymphocyte count with rIL-2 treatment is
associated with tumour response.
The addition of FAA to rIL-2 did not produce any
marked improvement despite the encouraging animal studies.
However, the combination did not increase toxicity over that
reported with rIL-2 alone and no patient required intensive
care facilities. Further studies using rIL-2 in combination
with other biological response modifiers, e.g. interferon and
tumour necrosis factor, and with chemotherapeutic agents,
such as DTIC, in malignant melanoma require further ex-
ploration.
The authors acknowledge Eurocetus Corporation, Amsterdam, for
the generous donation of recombinant interleukin-2 and Lipha,
Lyon, for the flavone acetic acid used in this study.
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